Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noting a discrepancy in the request metadata which listed "Avalo Therapeutics, Inc.") on February 2, 2016. The filing primarily addresses regulatory disclosure (Regulation FD) and other events regarding the company's clinical trial activities for its lead candidate, CERC-501.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational milestones and clinical trial status rather than financial performance.
Material Changes and Operational Events
- Smoking Cessation Trial Initiation: Cerecor announced the enrollment of its first subject in a Phase 2 clinical trial for CERC-501 for smoking cessation. The study is a 30-day, double-blind, placebo-controlled, crossover design targeting heavy smokers not currently seeking treatment, with an assumed enrollment of 66 subjects.
- Depression Trial Discontinuation: The National Institutes of Health (NIH) discontinued the NIMH-funded Phase 2 clinical trial for CERC-501 in treatment-resistant depression, which was sponsored by Massachusetts General Hospital. The stated reason for discontinuation was slow study progression.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on future earnings. The primary risk highlighted is the operational challenge of slow study progression, which led to the discontinuation of the depression trial. The company is proceeding with the smoking cessation trial as a separate initiative.
Key Facts for Investor Verification
- Verify the current status and enrollment progress of the CERC-501 smoking cessation Phase 2 trial.
- Confirm the financial impact of the discontinued depression trial and any remaining obligations to the NIH or Massachusetts General Hospital.
- Review the company's cash runway and funding status, as this filing does not disclose liquidity metrics.
- Clarify the discrepancy between the request metadata ("Avalo Therapeutics") and the filing registrant ("Cerecor Inc.").